RedHill Biopharma Ltd. — Form 6-K Summary
Reporting context: Filed October 7, 2026, reporting a Nasdaq listing-compliance update for October 2026.
Nasdaq bid-price compliance
- Nasdaq granted the Company an additional 180 calendar days, through April 5, 2027, to regain compliance with the $1.00 minimum bid-price requirement under Nasdaq Listing Rule 5550(a)(2).
- The deficiency arose because the ADS closing bid price was below $1.00 for 30 consecutive business days. Nasdaq first notified the Company on April 8, 2026, and the initial compliance period expired October 5, 2026.
- Compliance can be restored if the ADS closing bid price reaches at least $1.00 for a minimum of 10 consecutive business days before April 5, 2027.
- Each ADS represents 10,000 ordinary shares. The ADSs continue to trade on the Nasdaq Capital Market under ticker RDHL; the notification has no immediate effect on listing or trading.
- The Company stated that it meets the other applicable continued-listing requirements, including the market-value-of-publicly-held-shares requirement.
Financial results and material changes
This 6-K reports no revenue, earnings, cash flow, margin, debt, liquidity, or other operating financial metrics. It describes a compliance-period extension, not a financial-results update.
Management outlook and risks
The Company intends to monitor its ADS bid price and, if needed, consider options to regain compliance before the extended deadline. Failure to meet the requirement by April 5, 2027 could put the Nasdaq listing at risk; the filing does not specify which compliance options may be pursued.
Investor verification points
- Track whether the ADS closing bid price reaches at least $1.00 for 10 consecutive business days and whether Nasdaq confirms compliance.
- Check for subsequent company disclosures on any actions taken to regain compliance and the status of the Nasdaq listing.
- Note that this 6-K is incorporated by reference into the Company’s specified Form S-8 and Form F-3 registration statements.